THERAPY APPROVAL PATHWAYS IN JAPAN: ACCELERATED, CONDITIONAL AND EMERGENCY AUTHORIZATIONS

1. INTRODUCTION

Therapy approval pathways refer to the legal and regulatory procedures through which medicines, biological products, gene therapies, regenerative medicine products and other medical treatments receive authorization for clinical use.

Japan has established different approval mechanisms to facilitate access to innovative therapies while maintaining appropriate standards of safety, quality and efficacy.

These mechanisms include:

Standard marketing authorization.

Priority review and accelerated development programmes.

Conditional and time-limited approval.

Conditional early approval for certain serious diseases.

Emergency approval under the Pharmaceuticals and Medical Devices Act (PMD Act).

The principal regulatory authorities are the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA).

The legal objective is to balance timely patient access, scientific evidence, medical necessity and continuing post-approval safety monitoring.

2. LEGAL AND REGULATORY FRAMEWORK

A. Pharmaceuticals and Medical Devices Act (PMD Act)

The PMD Act provides Japan's principal legal framework for pharmaceutical and medical-product authorization.

Article 14 establishes the marketing authorization framework for pharmaceuticals and related products.

The approval assessment considers:

Quality and manufacturing consistency.

Safety and adverse-reaction information.

Scientific evidence of efficacy.

Reliability of clinical trial data.

Manufacturing and quality-management compliance.

The MHLW makes relevant regulatory decisions, supported by scientific and technical assessments conducted by PMDA.

B. Priority Review and Accelerated Development

Japan operates priority review arrangements for medicines addressing serious diseases and significant unmet medical needs.

The Sakigake Designation System, introduced in 2015, promotes early development and expedited regulatory review of innovative medical products.

Its objectives include:

Earlier access to promising therapies.

Priority regulatory consultation.

Expedited review.

Enhanced development support.

Improved coordination between applicants and regulators.

Priority review does not eliminate the requirement to establish an acceptable benefit-risk profile.

C. Conditional Early Approval System

Japan introduced a conditional early approval system for certain medicines addressing serious diseases where conventional clinical development may be difficult.

The framework permits approval based on an appropriate assessment of available evidence, taking account of unmet medical needs and the feasibility of obtaining further clinical data.

Important considerations include:

Seriousness of the disease.

Lack of satisfactory alternative treatments.

Scientific plausibility of efficacy.

Available clinical evidence.

Ability to conduct further post-marketing investigations.

D. Emergency Approval System

Japan introduced an emergency approval framework through amendments to the PMD Act in 2022.

The system is intended to facilitate access to medical products during qualifying public-health emergencies.

It permits emergency authorization under specified statutory conditions where conventional efficacy evidence may not yet be fully available, provided the applicable safety requirements and reasonable expectations of efficacy are satisfied.

Emergency approval is subject to conditions and time limitations. It is not an unrestricted waiver of pharmaceutical safety requirements.

3. CONDITIONAL AND EMERGENCY APPROVAL REQUIREMENTS

A. Conditional Approval

The PMD Act provides a statutory conditional approval mechanism under Article 14-2-2.

Under the revised framework effective 1 May 2026, approval may be granted subject to conditions where:

The medicine has particularly high medical necessity.

Its intended therapeutic efficacy can reasonably be predicted.

Its expected benefits are not outweighed by seriously harmful effects.

Further investigation of quality, efficacy and safety is required.

Appropriate post-approval risk-management measures can be imposed.

The authorization holder must conduct the required investigations and submit the resulting information to MHLW.

B. Emergency Approval

Article 14-2-2-2 establishes the emergency approval mechanism.

Its principal requirements are:

An urgent need to prevent the spread of a serious disease or expansion of public-health damage.

No appropriate alternative method of addressing the emergency.

A reasonable expectation that the product will have the claimed efficacy.

No reasonable expectation that serious adverse effects will make the product unsuitable for use.

Compliance with conditions imposed by MHLW.

Emergency approval may be granted for a period not exceeding two years. The authorization is subject to legally prescribed conditions and time limitations.

C. Post-Approval Monitoring

Conditional and emergency authorizations require continuing safety oversight.

Companies may be required to conduct additional investigations, submit safety information, maintain pharmacovigilance arrangements and comply with restrictions on appropriate use.

4. IMPORTANT JAPANESE CASE LAWS

There is no Supreme Court judgment specifically establishing judicial rules for Sakigake, conditional early approval or emergency authorization. The following pharmaceutical cases provide relevant analogous legal principles.

1. Chloroquine Drug Injury Case – Supreme Court, 23 June 1995.

The Court examined pharmaceutical regulatory responsibility in connection with serious injuries associated with chloroquine.

Principle: Regulatory authorities must exercise their statutory powers appropriately in light of available scientific knowledge and foreseeable pharmaceutical risks.

2. Iressa Litigation – Tokyo District Court, 23 March 2011.

The court examined gefitinib's usefulness and the adequacy of warnings concerning interstitial pneumonia. It recognized certain manufacturer and government liabilities.

Principle: Regulatory approval must be accompanied by appropriate communication of serious safety risks.

3. Iressa Litigation – Osaka District Court, 25 February 2011.

The court considered pharmaceutical safety and regulatory responsibility in relation to gefitinib.

Principle: The benefits of an innovative medicine must be evaluated alongside foreseeable serious adverse effects.

4. Iressa Litigation – Tokyo High Court, 15 November 2011.

The appellate court rejected the relevant claims against the manufacturer and government.

Principle: Pharmaceutical liability requires careful assessment of scientific knowledge and the legal standards applicable when approval was granted.

5. Iressa Litigation – Osaka High Court, 25 May 2012.

The court reconsidered the lower-court findings and rejected the relevant claims.

Principle: Judicial review of pharmaceutical decisions requires examination of the evidence and the applicable regulatory standards.

6. Iressa Supreme Court Proceedings – 12 April 2013.

The Supreme Court proceedings addressed pharmaceutical warning obligations and the foreseeability of serious adverse reactions.

Principle: Manufacturers must provide appropriate safety information based on scientific knowledge available at the relevant time.

7. HIV-Contaminated Blood Products Litigation – Tokyo and Osaka District Courts, settlement of 29 March 1996.

The litigation concerned HIV infections caused by contaminated blood products and failures involving pharmaceutical safety oversight.

Principle: Delayed regulatory action and inadequate pharmaceutical safety management can have serious consequences for public health.

This was a court-mediated settlement rather than a final merits judgment.

5. LIABILITY AND REGULATORY CONSEQUENCES

Non-compliance with approval conditions may result in:

Suspension or cancellation of marketing authorization.

Additional clinical or post-marketing investigations.

Product recalls and safety communications.

Administrative corrective orders.

Civil compensation claims.

Criminal liability where statutory offences are established.

6. PRACTICAL COMPLIANCE REQUIREMENTS

Pharmaceutical companies should maintain scientific evidence supporting approval, documented benefit-risk assessments, clinical trial records, pharmacovigilance systems, post-marketing investigation plans, manufacturing quality documentation and procedures for reporting serious adverse reactions.

They must also ensure that approval conditions are communicated to healthcare professionals and that significant new safety findings are promptly evaluated.

7. CONCLUSION

Japan's therapy approval pathways combine conventional authorization, priority review, Sakigake designation, conditional approval and emergency authorization. The PMD Act establishes the statutory framework, while PMDA provides scientific and technical assessments supporting regulatory decisions.

The 2026 statutory amendments are particularly important because they clarify conditional approval and emergency authorization requirements. The Iressa, chloroquine and HIV-contaminated blood-product proceedings demonstrate the continuing importance of scientific evidence, patient safety, adequate warnings and regulatory accountability.

Ultimately, accelerated access does not eliminate the obligation to protect patients. Japan's framework seeks to balance medical innovation and urgent therapeutic needs with evidence-based approval, continuing safety monitoring and enforceable regulatory conditions.